申请人:Tadeka Chemical Industries, Ltd.
公开号:EP1227090A1
公开(公告)日:2002-07-31
A compound of the formula: wherein
X and X' are the same or different, and each represents a hydrogen atom, a fluorine atom, a chlorine atom or an amino optionally having substituents, and at least one of X and X' represents a fluorine atom, a chlorine atom or an amino optionally having substituents;
R1 and R2 represent a hydrogen atom or C1-6 alkyl optionally having substituents, or R1 and R2, together with the adjacent nitrogen atom, form a nitrogen-containing heterocyclic ring optionally having substituents;
Y and Q are the same or different, and each represents a bond or a spacer having a main chain of 1 to 6 atoms;
... represents a single bond or a double bond;
T1 and T2 are the same or different, and each represents C(R9) (R9 represents a hydrogen atom, a hydroxy or C1-6 alkyl) or N, when each of the adjacent ... is a single bond, and C when the adjacent ... is a double bond; and
Ar represents an aromatic group optionally having substituents, a C3-9 cycloalkyl group optionally having substituents, a 3 to 9-membered saturated heterocyclic group optionally having substituents, a hydrogen atom or a halogen atom; provided that 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-(4-phenylpiperazin-1-yl)carbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline; 6-chloro-3-(R,S)-(N,N-dimethylamino)methyl-1-[3-(indol-3-yl)-2-[(R)-4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidinocarbonylamino]propanoyl]-1,2,3,4-tetrahydroquinoline and 1-benzoyl-N-[(R)-2-[6-chloro-3-[(N,N-dimethylamino)methyl]-1,2,3,4-tetrahydroquinolin-1-yl]-1-[3-(indol-3-yl)propanoyl]-4-piperidinecarboxamide are excluded; a salt thereof or a prodrug thereof has an excellent somatostatin receptor binding inhibition action and is useful for preventing and/or treating diseases associated with somatostatin.
式中的化合物
X和X'相同或不同,各自代表氢原子、氟原子、氯原子或可选具有取代基的氨基,且X和X'中至少有一个代表氟原子、氯原子或可选具有取代基的氨基;
R1 和 R2 代表氢原子或任选具有取代基的 C1-6 烷基,或 R1 和 R2 与相邻的氮原子一起形成任选具有取代基的含氮杂环;
Y 和 Q 相同或不同,各自代表主链为 1 至 6 个原子的键或间隔物;
代表单键或双键;
T1 和 T2 相同或不同,当相邻......中的每一个为单键时,各自代表 C(R9)(R9 代表氢原子、羟基或 C1-6 烷基)或 N,当相邻......中的每一个为双键时,各自代表 C;以及
Ar 代表任选具有取代基的芳香基、任选具有取代基的 C3-9 环烷基、任选具有取代基的 3-9 元饱和杂环基、氢原子或卤素原子;条件是 6-氯-3-(R,S)-(N,N-二甲基氨基)甲基-1-[3-(吲哚-3-基)-2-[(R)-(4-苯基哌嗪-1-基)羰基氨基]丙酰基]-1,2,3,4-四氢喹啉;6-氯-3-(R,S)-(N,N-二甲基氨基)甲基-1-[3-(吲哚-3-基)-2-[(R)-4-(2-氧代-2,3-二氢-1H-苯并咪唑-1-基)哌啶甲酰氨基]丙酰基]-1,2,3,4-四氢喹啉不包括 1-苯甲酰基-N-[(R)-2-[6-氯-3-[(N,N-二甲基氨基)甲基]-1,2,3,4-四氢喹啉-1-基]-1-[3-(吲哚-3-基)丙酰基]-4-哌啶甲酰胺;其盐或其原药具有优异的抑制体生长抑素受体结合的作用,可用于预防和/或治疗与体生长抑素相关的疾病。